Eaton Vance Management Biohaven Pharmaceutical Holding CO Ltd. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Biohaven Pharmaceutical Holding CO Ltd. stock. As of the latest transaction made, Eaton Vance Management holds 35,908 shares of BHVN stock, worth $1.49 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,908
Previous 34,709
3.45%
Holding current value
$1.49 Million
Previous $5.06 Million
7.34%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding BHVN
# of Institutions
11Shares Held
792KCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL710KShares$29.4 Million17.51% of portfolio
-
S. Muoio & Co. LLC New York, NY19KShares$786,5313.79% of portfolio
-
Agf Investments LLC Boston, MA11.6KShares$479,0460.16% of portfolio
-
Birchview Capital, LP Burlington, VT7.37KShares$305,2050.34% of portfolio
-
Brevan Howard Capital Management LP St. Helier, Y96.52KShares$270,3130.0% of portfolio
About Biohaven Pharmaceutical Holding Co Ltd.
- Ticker BHVN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,645,000
- Market Cap $2.97B
- Description
- Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...